Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)

NCT01578720 is registered in ClinicalTrials.gov with Retina Research Institute, LLC as lead sponsor.

NCT NCT01578720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01578720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)
Lead sponsor
Retina Research Institute, LLC
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
March 31, 2015
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascularization, presumed ocular histoplasmosis